Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
VIVO's Cash to Debt is ranked higher than
98% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.28 vs. VIVO: No Debt )
Ranked among companies with meaningful Cash to Debt only.
VIVO' s 10-Year Cash to Debt Range
Min: 0.07  Med: 6.12 Max: No Debt
Current: No Debt
Equity to Asset 0.91
VIVO's Equity to Asset is ranked higher than
95% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. VIVO: 0.91 )
Ranked among companies with meaningful Equity to Asset only.
VIVO' s 10-Year Equity to Asset Range
Min: 0.35  Med: 0.76 Max: 0.92
Current: 0.91
0.35
0.92
Interest Coverage No Debt
VIVO's Interest Coverage is ranked higher than
95% of the 100 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1009.34 vs. VIVO: No Debt )
Ranked among companies with meaningful Interest Coverage only.
VIVO' s 10-Year Interest Coverage Range
Min: 4.78  Med: 26.40 Max: 9999.99
Current: No Debt
4.78
9999.99
F-Score: 6
Z-Score: 34.27
M-Score: -2.60
WACC vs ROIC
11.78%
30.34%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 28.16
VIVO's Operating margin (%) is ranked higher than
96% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.05 vs. VIVO: 28.16 )
Ranked among companies with meaningful Operating margin (%) only.
VIVO' s 10-Year Operating margin (%) Range
Min: -22.13  Med: 25.80 Max: 32.9
Current: 28.16
-22.13
32.9
Net-margin (%) 18.13
VIVO's Net-margin (%) is ranked higher than
93% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.79 vs. VIVO: 18.13 )
Ranked among companies with meaningful Net-margin (%) only.
VIVO' s 10-Year Net-margin (%) Range
Min: -18.18  Med: 16.86 Max: 22.09
Current: 18.13
-18.18
22.09
ROE (%) 21.80
VIVO's ROE (%) is ranked higher than
92% of the 175 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.52 vs. VIVO: 21.80 )
Ranked among companies with meaningful ROE (%) only.
VIVO' s 10-Year ROE (%) Range
Min: -34.51  Med: 21.66 Max: 30.41
Current: 21.8
-34.51
30.41
ROA (%) 19.79
VIVO's ROA (%) is ranked higher than
97% of the 190 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.05 vs. VIVO: 19.79 )
Ranked among companies with meaningful ROA (%) only.
VIVO' s 10-Year ROA (%) Range
Min: -13.69  Med: 14.05 Max: 22.5
Current: 19.79
-13.69
22.5
ROC (Joel Greenblatt) (%) 65.30
VIVO's ROC (Joel Greenblatt) (%) is ranked higher than
88% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.58 vs. VIVO: 65.30 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
VIVO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -30.75  Med: 56.53 Max: 89.27
Current: 65.3
-30.75
89.27
Revenue Growth (3Y)(%) 5.30
VIVO's Revenue Growth (3Y)(%) is ranked lower than
52% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.10 vs. VIVO: 5.30 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
VIVO' s 10-Year Revenue Growth (3Y)(%) Range
Min: 2.8  Med: 9.20 Max: 22.6
Current: 5.3
2.8
22.6
EBITDA Growth (3Y)(%) 7.50
VIVO's EBITDA Growth (3Y)(%) is ranked higher than
59% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.30 vs. VIVO: 7.50 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
VIVO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -2.3  Med: 6.70 Max: 22.5
Current: 7.5
-2.3
22.5
EPS Growth (3Y)(%) 8.50
VIVO's EPS Growth (3Y)(%) is ranked higher than
59% of the 102 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.40 vs. VIVO: 8.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
VIVO' s 10-Year EPS Growth (3Y)(%) Range
Min: -27.9  Med: 8.50 Max: 35.7
Current: 8.5
-27.9
35.7
» VIVO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

VIVO Guru Trades in Q3 2014

Chuck Royce 194,000 sh (+1104.97%)
Paul Tudor Jones 24,390 sh (+124.03%)
Jim Simons 794,576 sh (+14.28%)
Mario Gabelli 140,000 sh (+7.69%)
John Hussman 7,500 sh (unchged)
John Keeley 97,910 sh (-4.49%)
Joel Greenblatt 53,627 sh (-13.00%)
» More
Q4 2014

VIVO Guru Trades in Q4 2014

Paul Tudor Jones 40,834 sh (+67.42%)
Chuck Royce 269,500 sh (+38.92%)
Jim Simons 961,876 sh (+21.06%)
Joel Greenblatt 59,437 sh (+10.83%)
John Hussman Sold Out
Mario Gabelli 139,000 sh (-0.71%)
John Keeley 94,510 sh (-3.47%)
» More
Q1 2015

VIVO Guru Trades in Q1 2015

Joel Greenblatt 283,062 sh (+376.24%)
Mario Gabelli 139,000 sh (unchged)
John Keeley 92,510 sh (-2.12%)
Jim Simons 825,176 sh (-14.21%)
Chuck Royce 214,800 sh (-20.30%)
Paul Tudor Jones 29,125 sh (-28.67%)
» More
Q2 2015

VIVO Guru Trades in Q2 2015

Jim Simons 1,204,676 sh (+45.99%)
John Keeley 101,460 sh (+9.67%)
Paul Tudor Jones 30,225 sh (+3.78%)
Mario Gabelli 139,000 sh (unchged)
Joel Greenblatt 271,315 sh (-4.15%)
Chuck Royce 139,300 sh (-35.15%)
» More
» Details

Insider Trades

Latest Guru Trades with VIVO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 22.60
VIVO's P/E(ttm) is ranked higher than
73% of the 84 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.10 vs. VIVO: 22.60 )
Ranked among companies with meaningful P/E(ttm) only.
VIVO' s 10-Year P/E(ttm) Range
Min: 19.27  Med: 27.91 Max: 48.85
Current: 22.6
19.27
48.85
Forward P/E 20.79
VIVO's Forward P/E is ranked higher than
52% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.12 vs. VIVO: 20.79 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 22.50
VIVO's PE(NRI) is ranked higher than
74% of the 84 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.30 vs. VIVO: 22.50 )
Ranked among companies with meaningful PE(NRI) only.
VIVO' s 10-Year PE(NRI) Range
Min: 19.2  Med: 27.62 Max: 49
Current: 22.5
19.2
49
P/B 4.86
VIVO's P/B is ranked lower than
65% of the 168 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.33 vs. VIVO: 4.86 )
Ranked among companies with meaningful P/B only.
VIVO' s 10-Year P/B Range
Min: 4.12  Med: 6.35 Max: 11.74
Current: 4.86
4.12
11.74
P/S 4.11
VIVO's P/S is ranked lower than
59% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.99 vs. VIVO: 4.11 )
Ranked among companies with meaningful P/S only.
VIVO' s 10-Year P/S Range
Min: 2.28  Med: 5.32 Max: 10.95
Current: 4.11
2.28
10.95
PFCF 19.70
VIVO's PFCF is ranked higher than
75% of the 67 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.28 vs. VIVO: 19.70 )
Ranked among companies with meaningful PFCF only.
VIVO' s 10-Year PFCF Range
Min: 17.3  Med: 32.61 Max: 94.67
Current: 19.7
17.3
94.67
POCF 17.53
VIVO's POCF is ranked higher than
64% of the 84 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.83 vs. VIVO: 17.53 )
Ranked among companies with meaningful POCF only.
VIVO' s 10-Year POCF Range
Min: 14.22  Med: 26.48 Max: 49.75
Current: 17.53
14.22
49.75
EV-to-EBIT 13.72
VIVO's EV-to-EBIT is ranked higher than
78% of the 93 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.60 vs. VIVO: 13.72 )
Ranked among companies with meaningful EV-to-EBIT only.
VIVO' s 10-Year EV-to-EBIT Range
Min: 11.8  Med: 18.20 Max: 37.1
Current: 13.72
11.8
37.1
PEG 5.77
VIVO's PEG is ranked lower than
71% of the 41 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.25 vs. VIVO: 5.77 )
Ranked among companies with meaningful PEG only.
VIVO' s 10-Year PEG Range
Min: 0.98  Med: 2.86 Max: 39.94
Current: 5.77
0.98
39.94
Shiller P/E 23.29
VIVO's Shiller P/E is ranked higher than
65% of the 55 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.03 vs. VIVO: 23.29 )
Ranked among companies with meaningful Shiller P/E only.
VIVO' s 10-Year Shiller P/E Range
Min: 19.68  Med: 35.67 Max: 105.81
Current: 23.29
19.68
105.81
Current Ratio 8.88
VIVO's Current Ratio is ranked higher than
90% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.49 vs. VIVO: 8.88 )
Ranked among companies with meaningful Current Ratio only.
VIVO' s 10-Year Current Ratio Range
Min: 1.85  Med: 5.37 Max: 10.21
Current: 8.88
1.85
10.21
Quick Ratio 6.35
VIVO's Quick Ratio is ranked higher than
83% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.21 vs. VIVO: 6.35 )
Ranked among companies with meaningful Quick Ratio only.
VIVO' s 10-Year Quick Ratio Range
Min: 1.06  Med: 3.60 Max: 8.77
Current: 6.35
1.06
8.77
Days Inventory 171.89
VIVO's Days Inventory is ranked lower than
84% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 77.75 vs. VIVO: 171.89 )
Ranked among companies with meaningful Days Inventory only.
VIVO' s 10-Year Days Inventory Range
Min: 130.86  Med: 179.29 Max: 283.57
Current: 171.89
130.86
283.57
Days Sales Outstanding 52.49
VIVO's Days Sales Outstanding is ranked higher than
65% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 65.30 vs. VIVO: 52.49 )
Ranked among companies with meaningful Days Sales Outstanding only.
VIVO' s 10-Year Days Sales Outstanding Range
Min: 44.91  Med: 73.05 Max: 114.22
Current: 52.49
44.91
114.22

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 4.19
VIVO's Dividend Yield is ranked higher than
91% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.42 vs. VIVO: 4.19 )
Ranked among companies with meaningful Dividend Yield only.
VIVO' s 10-Year Dividend Yield Range
Min: 1.24  Med: 3.14 Max: 4.96
Current: 4.19
1.24
4.96
Dividend Payout 0.95
VIVO's Dividend Payout is ranked lower than
76% of the 49 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.33 vs. VIVO: 0.95 )
Ranked among companies with meaningful Dividend Payout only.
VIVO' s 10-Year Dividend Payout Range
Min: 0.27  Med: 0.73 Max: 5.8
Current: 0.95
0.27
5.8
Dividend growth (3y) 1.30
VIVO's Dividend growth (3y) is ranked lower than
67% of the 21 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9.50 vs. VIVO: 1.30 )
Ranked among companies with meaningful Dividend growth (3y) only.
VIVO' s 10-Year Dividend growth (3y) Range
Min: 0.9  Med: 15.90 Max: 37.5
Current: 1.3
0.9
37.5
Yield on cost (5-Year) 4.87
VIVO's Yield on cost (5-Year) is ranked higher than
84% of the 85 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. VIVO: 4.87 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
VIVO' s 10-Year Yield on cost (5-Year) Range
Min: 1.44  Med: 3.66 Max: 5.78
Current: 4.87
1.44
5.78
Share Buyback Rate -0.40
VIVO's Share Buyback Rate is ranked higher than
77% of the 111 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.60 vs. VIVO: -0.40 )
Ranked among companies with meaningful Share Buyback Rate only.
VIVO' s 10-Year Share Buyback Rate Range
Min: 0.3  Med: -0.70 Max: -6.1
Current: -0.4

Valuation & Return

vs
industry
vs
history
Price/Net Cash 26.17
VIVO's Price/Net Cash is ranked lower than
77% of the 60 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.50 vs. VIVO: 26.17 )
Ranked among companies with meaningful Price/Net Cash only.
VIVO' s 10-Year Price/Net Cash Range
Min: 14.91  Med: 43.27 Max: 172.21
Current: 26.17
14.91
172.21
Price/Net Current Asset Value 7.77
VIVO's Price/Net Current Asset Value is ranked higher than
51% of the 108 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 7.45 vs. VIVO: 7.77 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
VIVO' s 10-Year Price/Net Current Asset Value Range
Min: 7  Med: 11.60 Max: 66.59
Current: 7.77
7
66.59
Price/Tangible Book 5.92
VIVO's Price/Tangible Book is ranked lower than
57% of the 145 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.76 vs. VIVO: 5.92 )
Ranked among companies with meaningful Price/Tangible Book only.
VIVO' s 10-Year Price/Tangible Book Range
Min: 3.58  Med: 8.85 Max: 13.61
Current: 5.92
3.58
13.61
Price/Projected FCF 1.76
VIVO's Price/Projected FCF is ranked higher than
61% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.01 vs. VIVO: 1.76 )
Ranked among companies with meaningful Price/Projected FCF only.
VIVO' s 10-Year Price/Projected FCF Range
Min: 1.17  Med: 2.62 Max: 4.42
Current: 1.76
1.17
4.42
Price/DCF (Earnings Based) 1.48
VIVO's Price/DCF (Earnings Based) is ranked higher than
80% of the 15 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. VIVO: 1.48 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 0.77
VIVO's Price/Median PS Value is ranked higher than
74% of the 158 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.02 vs. VIVO: 0.77 )
Ranked among companies with meaningful Price/Median PS Value only.
VIVO' s 10-Year Price/Median PS Value Range
Min: 0.12  Med: 0.90 Max: 1.95
Current: 0.77
0.12
1.95
Price/Peter Lynch Fair Value 2.88
VIVO's Price/Peter Lynch Fair Value is ranked lower than
65% of the 26 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.86 vs. VIVO: 2.88 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
VIVO' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.61  Med: 1.82 Max: 7.26
Current: 2.88
0.61
7.26
Price/Graham Number 2.44
VIVO's Price/Graham Number is ranked higher than
57% of the 63 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.82 vs. VIVO: 2.44 )
Ranked among companies with meaningful Price/Graham Number only.
VIVO' s 10-Year Price/Graham Number Range
Min: 1.99  Med: 3.17 Max: 5.47
Current: 2.44
1.99
5.47
Earnings Yield (Greenblatt) (%) 7.30
VIVO's Earnings Yield (Greenblatt) (%) is ranked higher than
89% of the 183 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.40 vs. VIVO: 7.30 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
VIVO' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 2.7  Med: 5.50 Max: 8.5
Current: 7.3
2.7
8.5
Forward Rate of Return (Yacktman) (%) 11.75
VIVO's Forward Rate of Return (Yacktman) (%) is ranked higher than
56% of the 55 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.53 vs. VIVO: 11.75 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
VIVO' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 1.5  Med: 10.00 Max: 26.8
Current: 11.75
1.5
26.8

Analyst Estimate

Sep15 Sep16
Revenue(Mil) 197 206
EPS($) 0.86 0.92
EPS without NRI($) 0.86 0.92

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:LH, ALR, DGX, LIFE, ENZ » details
Traded in other countries:MR4.Germany,
Meridian Bioscience Inc was incorporated in Ohio in 1976. It is a fully-integrated life science company involved in the development, manufacture, sale and distribution of diagnostic test kits, mainly for certain respiratory, gastrointestinal, viral and parasitic infectious diseases. It also manufactures and distributes bulk antigens, antibodies and reagents used by researchers and other diagnostic manufacturers and the contract development. The Company is involved in manufacturing of proteins and other biological products used by bio-pharmaceutical and biotechnology companies engaged in research for new drugs and vaccines. The Companys operating segments are Diagnostics and Life Science. The Companys U.S. Diagnostics segment focuses on the development, manufacture, sale and distribution of diagnostic test kits, primarily for certain gastrointestinal, viral, respiratory and parasitic infectious diseases. Its European Diagnostics segment focuses on the sale and distribution of diagnostic test kits, manufactured both by the Companys U.S. Diagnostics segment and by third-party vendors. Life Science segment focuses on the development, manufacture, sale and distribution of bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, competent cells and bio-research reagents used by researchers and other diagnostic companies, as well as contract development and manufacturing services under clinical cGMP conditions. It has operations in Memphis, Tennessee; Boca Raton, Florida; London, England; Luckenwalde, Germany; and Sydney, Australia. The products in both segment includes Molecular tests, Immunoassay tests, Molecular components, Immunoassay components. The Companys competitors are Abbott Laboratories Inc., Becton, Dickinson and Company, Thermo Fisher and Siemens, Quidel Corporation and Inverness Medical Innovations. The diagnostic products are regulated by the Food & Drug Administration (FDA) as devices pursuant to the Federal Food, Drug, and Cosmetic Act (FDC).
» More Articles for VIVO

Headlines

Articles On GuruFocus.com
The Four Horsemen: Risk, Uncertainty, Price and Value Mar 19 2015 
Guru-Held Stocks Trading At Historical Low P/B Oct 08 2014 
Small-Cap Consensus Picks By The Investing Gurus Jul 25 2014 
13 Stocks Delivering What's Important: Dividend Increases Jan 27 2014 
68 Top Dividend Stocks with Ex-Dividend Date in August 2013 Jul 29 2013 
My 3 Favorite Healthcare Dividend Stocks with Highest Float Short Ratio Jun 03 2013 
20 Best Yielding Healthcare Growth Stocks and Which to Buy Feb 02 2013 
comment on VIVO Jan 26 2013 
16 Best Dividend Paying Healthcare Stocks Sep 03 2012 
15 of the Best Growing Dividend Achievers Jul 30 2012 

More From Other Websites
MERIDIAN BIOSCIENCE INC Financials Aug 20 2015
MERIDIAN BIOSCIENCE INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Aug 17 2015
Meridian Bioscience Elects Catherine Sazdanoff and John McIlwraith to the Board of Directors Aug 17 2015
Meridian Bioscience Elects Catherine Sazdanoff and John McIlwraith to the Board of Directors Aug 17 2015
10-Q for Meridian Bioscience, Inc. Aug 13 2015
MERIDIAN BIOSCIENCE INC Files SEC form 10-Q, Quarterly Report Aug 10 2015
MERIDIAN BIOSCIENCE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 07 2015
MERIDIAN BIOSCIENCE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 27 2015
Meridian Bioscience Q3 Earnings in Line, Keeps FY15 View - Analyst Blog Jul 27 2015
GBSN: Zacks SCR Initiates Coverage With Buy Rec Jul 23 2015
Meridian Bioscience Reports Third Quarter and Nine Months Operating Results, Declares Regular Cash... Jul 23 2015
Meridian Bioscience meets 3Q profit forecasts Jul 23 2015
Meridian Bioscience meets 3Q profit forecasts Jul 23 2015
Meridian Bioscience Reports Third Quarter and Nine Months Operating Results, Declares Regular Cash... Jul 23 2015
Meridian Bioscience Receives FDA Clearance for New Molecular Amplification Test: illumigene® HSV... Jul 20 2015
Meridian Bioscience Receives FDA Clearance for New Molecular Amplification Test: illumigene® HSV... Jul 20 2015
Meridian Bioscience Launches Para-Pak® SVT (Single Vial Transport) Jun 04 2015
Meridian Bioscience Launches Para-Pak® SVT (Single Vial Transport) Jun 04 2015
Meridian Bioscience Wins CE Mark for Herpes Virus Assays - Analyst Blog May 22 2015
Meridian Bioscience Europe Launches New Molecular Tests for the Detection of Herpes Simplex Virus... May 21 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK